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Abstract  
Aims. Changes in renal function have been associated with differential outcome in patients 
with acute heart failure (HF). However, individual trajectories of changes in renal function are 
unknown and it is unclear whether these relate to different clinical characteristics and clinical 
outcome. Our aim was to investigate the prognostic importance of individual trajectories of 
changes in renal function in acute HF.  
Methods and Results. This was a retrospective, observational analysis from the double-blind, 
randomized, placebo controlled PROTECT trial in acute HF patients. We identified and 
internally validated 8 different renal trajectories among 1897 patients by visual inspection of 
inhospital serum creatinine changes. The primary outcome measure was all-cause mortality at 
180 days. Mean age was 70±12 years, 70% were male, and mean baseline eGFR was 49.0 
mL/min/1.73m
2
. A total of eight different trajectories were established. The most prevalent 
trajectories were an inhospital bump (19.0%), a sustained increase (17.6%), and a dip (14.5%) 
in serum creatinine. Overall, clinical characteristics of patients within different trajectories 
were remarkably similar. Crude 180-day mortality rates ranged from 12.0% in the trajectory 
with no significant changes to 18.3% in trajectory of sustained increase without significant 
differences. Overall, after multivariable adjustment, there was no trajectory of changes in 
renal function that was associated with significantly better or worse outcomes.  
Conclusions. Trajectories of changes in renal function in acute HF differ considerably on 
patient level. Despite these differences, clinical characteristics and outcome were similar, 
therefore questioning the prognostic importance of changes in renal function in acute HF.  
 
Keywords: Acute Heart Failure, Individual Renal Patterns, Trajectories of Renal Function 
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Abbreviations and Acronyms 
ACE, angiotensin-converting enzyme; 
CKD, chronic kidney disease; 
WRF, worsening renal function; 
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Introduction 
Acute heart failure (HF) is a major health care problem affecting nearly one million new 
patients per year, and is associated with poor clinical outcome. (1,2)(3,4) When chronic 
kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) of <60 
mL/min/1.73m
2
, is present in acute HF, it is associated with twofold increased risks of 
mortality.(5) In addition to impaired baseline renal function, deterioration in renal function or 
worsening renal function (WRF) during hospitalization is frequently observed in patients with 
acute HF.(5-7) In a meta-analysis, WRF was associated with an increased risk of mortality 
and HF hospitalization in chronic HF patients with both reduced and preserved ejection 
fraction.(8) In acute HF, where WRF occurs in 20-30% of patients, deterioration was also 
associated with a significantly increased mortality risk.(5,9) On a population level, it has been 
shown that the mean change in renal function during hospitalization is reflected by an 
increase in serum creatinine that flattens during a longer inhospital stay, which is thought to 
be related to the great diversity in renal changes on patient level.(10) 
However, it is questionable whether this analysis was able to capture the individual 
heterogeneity of patterns of renal function, as we hypothesize that individual renal trajectories 
do not all strictly follow the homogeneous population trajectory. Therefore, we evaluated the 
presence of distinct different individual trajectories of changes in renal function in acute HF, 
and investigated the association with clinical characteristics and outcome in an analysis from 
the PROTECT study.  
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Methods 
Patients. Main design and findings of the Placebo-controlled Randomized Study of Selective 
A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute 
Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on 
Congestion and Renal Function (PROTECT) trial – a multicenter, randomized, double-blind, 
placebo-controlled phase III trial have been published.(11)(12) 
In short, 2033 patients with acute (decompensated) heart failure requiring IV diuretic therapy, 
with mild or moderate renal impairment (estimated creatinine clearance between 20 and 80 
mL/min), were randomized to Rolofylline or placebo. The main findings were neutral. Crucial 
exclusion criteria included a systolic blood pressure <90 or ≥160 mmHg, and ongoing or 
planned treatment with ultrafiltration or dialysis. All patients provided written informed 
consent. 
For the purpose of this analysis, we included all patients in the intention-to-treat population 
who were still alive at study day 7, had ≥ 3 serum creatinine measurements taken within the 
first 7 days of the study, had baseline creatinine measurements, and had additional follow-up 
for death and rehospitalization of ≥7 days. Using these criteria, the sample size for the present 
study was 1897 patients of the total study population (93%). Serum creatinine was assessed in 
a central laboratory (ICON Laboratories, Farmingdale, New York).  
 
Trajectory establishment and assessment. In a random sample of 200 patients of the 
population, three independent investigators (IB, KS, JTM) identified clusters of different renal 
trajectories in a blinded (for outcome and other characteristics) fashion. Each investigator 
investigated the individual trajectories of individual patients, blinded to the results of the other 
investigators. This was performed by visual inspection of each patient’s individual pattern of 
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serum creatinine when printed on Y-axis normalized for individual patient absolute creatinine 
values. Then, results were pooled and inconsistencies were solved by consensus, including 
assessment by a fourth investigator (KD). This resulted in eight distinct different renal 
trajectories.  
Subsequently, two researchers (IB and KS) individually assigned each patient of the entire 
study population to one of the eight trajectories in a blinded matter in a similar procedure. 
Afterwards, results were pooled and inconsistencies were solved by consensus, which again 
included assessment by a third investigator (KD). To check whether the level of agreement 
between the investigators was acceptable, inter-observer agreement was measured by Kappa 
statistics.  
 
Study outcomes. The primary outcome variable of interest was all-cause mortality at 180 
days. Secondary outcome included cardiovascular or renal rehospitalization at 60 days, and 
death or HF rehospitalization at 60 days. 
 
Statistical analysis. Symmetrical distributed continuous variables are presented as mean ± 
standard deviation, skewed data is presented as median and 25
th
-75
th
 percentile. Categorical 
variables are presented as numbers(percentage) (N(%)). Differences in baseline characteristics 
were evaluated using appropriate statistics, such as ANOVA statistics (normal distribution) or 
Kruskall-Wallis statistics (skewed data). Differences in proportions were assessed using χ
2
 
tests. Event rates at the time points of interest were presented using percentages and Kaplan-
Meier figures. Logarithmic transformations were applied to model nonlinear relationships. To 
evaluate the relationship between different trajectories and clinical outcome, a Cox 
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proportional hazard analysis was performed. For each continuous predictor, the assumption of 
linearity was checked. Multivariable adjustment was done in two steps. At first adjustment for 
baseline eGFR (calculated by the CKD-EPI formula)(13), and secondly a multivariable model 
based on a previously published 8-item prognostic model in this population, including the 
variables age, systolic blood pressure, edema, previous history of HF hospitalization, baseline 
serum albumin, blood urea nitrogen, creatinine and sodium.(14) Estimates are presented as 
hazard ratios (HR) with 95% confidence intervals (CI). As a sensitivity analysis and internal 
validation step, we also evaluated the trajectories of serum creatinine in each of the defined 
trajectories using a repeated measures, random effect model. Two tailed P-values <0.05 were 
considered statistically significant.  Statistical analyses were performed using IBM SPSS 
Statistics 23 (New York, USA), and R: a Language and Environment for Statistical 
Computing, version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).(15) 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
8 
 
Results 
Population. The study population consisted of 1897 patients, of which 70% were male, with a 
mean age of 70±12 years, LVEF of 32±13%, and baseline eGFR of 49±20 ml/min/1.73m
2
. 
Median diuretic response over 4 days was -0.39 (-0.80 to -0.14) kg/40 mg furosemide. 
 
Trajectories. First, we identified 8 renal trajectories identified by changes in creatinine, as 
seen in Figure 1. These included: a drop followed by a rise (‘Dip’), a rise followed by a drop 
(‘Bump’), a ’Dip followed by Bump’,  a ‘Bump followed by Dip’, a ‘Sustained Decrease’, a 
‘Sustained Increase’, ‘an (almost) absence of change (‘No Change’), and finally multiple 
significant fluctuations (‘Various Changes’) that fitted none of the other trajectories. 
The kappa value for the pilot study (200 patients) was 0.82 (0.77-0.86 95% CI), correlating 
with a strong level of agreement. After all 1897 patients were categorized to one of the eight 
trajectories, the kappa value was 0.85 (0.83-0.86 95% CI). In a sensitivity analysis, we 
retrospectively evaluated the trajectories of creatinine in each of the defined trajectories. The 
results of this validation step are shown in Supplementary Figure 1. This confirms the general 
slope of creatinine on a group level within each trajectory, with the exception of the ‘Various 
Changes’ trajectory, which probably represents a mixed bag with individual changes in 
creatinine that on a group level oppose one another, resulting in a horizontal slope.  
 
The distribution of the prevalence of different trajectories is shown in Figure 1, and ranges 
from 50 (2.6%) in ‘No Change’ to 360 (19.0%) in ‘Bump’.  
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Baseline Characteristics. Baseline characteristics of the different trajectories are shown in 
Table 1. Overall, characteristics among different trajectories were similar, and only small 
differences were observed. Notably, patients with trajectory ‘No Change’ were more likely to 
be male and had the highest body mass index, while patients with trajectory ‘Sustained 
Increase’ were the oldest. Trajectory ‘Sustained Decrease’ included patients who had the 
lowest LVEF (31±13%), and most frequently were in NYHA class IV (44%). Mean baseline 
eGFR, was lowest in this group, with a corresponding creatinine value of 1.60 (1.30-2.10) 
mg/dL. The trajectory ‘Dip followed by Bump’ included patients who had the highest 
prescription rates of angiotensin converting enzyme (ACE) inhibitor treatment. Regarding 
clinical symptoms, severe dyspnea was most frequently present in patients included in 
trajectory ‘Dip’ (88.8%). Trajectories ‘Sustained Increase’, ‘Bump’ and ‘No Change’ showed 
the worst diuretic responses: -0.33 (-0.78 to -0.10), -0.33 (-0.70 to -0.11), and -0.26 (-0.47 to -
0.14) kg/40 mg furosemide, respectively. Best diuretic response was found in trajectory 
‘Various Changes’: -0.46 (-0.97 to -0.16) kg/40mg furosemide (P-value=0.001). 
Hemoconcentration, defined as an increase in hemoglobin from admission to day 7 (or 
discharge) varied between 48% (Drop) and 67% (Pancake), but was not significantly different 
between trajectories. 
 
Renal trajectories and Clinical outcome. 
During follow up, 301 (15.9%) of 1897 patients experienced the primary outcome of all-cause 
mortality at day 180. Among all renal trajectories, differences in mortality were small and not 
significantly different. In the trajectory with a sustained increase in creatinine 61 patients 
(18.3%) experienced the primary endpoint of all-cause mortality. In the trajectory of sustained 
decrease, which represents the opposite of the sustained increase trajectory, 48 patients 
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(18.2%) experienced the primary outcome. Notably, the trajectory with an almost absence of 
change in renal function, ‘No Change’, had the lowest mortality rate, as 6 patients (12.0%) 
experienced all-cause mortality at 180 days. 
The Kaplan-Meier figure for the primary outcome, mortality at 180 days, among renal 
trajectories is depicted in Figure 2 (Logrank p-value of 0.51) and showed, in general, similar 
outcome for all groups.  
In Cox regression analysis, using the trajectory ‘No Change’ as reference category (no change 
in serum creatinine which showed the best outcome in the Kaplan-Meier survival analysis), 
the highest mortality risk was observed for both trajectory ‘Sustained Decrease’ (HR 1.58, 
95% Confidence Interval (CI) 0.68 to 3.70) and trajectory ‘Sustained Increase’ (HR 1.59, 95% 
CI 0.69 to 3.68). However, these differences did not reach statistical significance (P-value 
0.29 and 0.28, respectively, Table 2). Other trajectories showed a similar pattern, without 
evidence of increased or decreased risk with one particular trajectory.  
In multivariable Cox regression analysis, after adjustment for baseline eGFR, similar findings 
remained (Table 2). Whereas eGFR at baseline itself was a powerful predictor of mortality, 
none of the trajectories showed a significant association with increased mortality rates. Even 
when adjusted for baseline diuretic response, no significant differences were found. Finally, 
after adjustment for the 8 –variable multivariable model, the results remained largely 
unchanged. 
The secondary combined endpoint of death or cardiovascular or renal rehospitalization at day 
60 (Figure 3) showed similar results for all trajectories. However, a trend was observed in 
favor of the fluctuating trajectory ‘Various Changes’ regarding all the secondary outcomes in 
unadjusted analyses, whereas trajectory ‘No Change’ showed the worst outcome. However, in 
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Cox regression analysis and after multivariable adjustment, no statistically significant 
differences between the trajectories were observed. 
Discussion 
This study was designed to identify patterns of changes in renal function during a hospital 
admission for acute HF, and relate these patterns to different clinical characteristics and 
outcome. Our results show that despite marked differences in patterns as determined on an 
individual patient level, differences in clinical characteristics and clinical outcome were small. 
 
Epidemiology of renal trajectories 
In acute heart failure, 20-30% of patients experience deterioration or worsening renal function 
during hospitalization.(5)(16) This mean change in renal function on a heart failure population 
level is reflected by an increase in serum creatinine that reaches a plateau during a longer 
inhospital stay.(10) However, since the overall characteristics of the acute heart failure 
population are characterized by a great heterogeneity, this may also hold true for patterns of 
changes in renal function.(17) More evidence of this heterogeneity of the heart failure 
population is also stressed by a recent meta-analysis, where findings suggest that not only the 
clinical setting, but also the cause of WRF, and associated hemodynamic changes are of major 
importance for evaluating the significance of WRF.(5)  In a smaller study in 401 ADHF 
patients, WRF occurred in 21.2% (defined as ≥20% change in GFR) while also an 
improvement in renal function (identified by a decrease in creatinine -similar to the trajectory 
‘Sustained Decrease’ in our study) occurred in 16.2% of the population.(18) Overall, in this 
small study, baseline characteristics of both worsening and improving renal function were 
similar.(19) Despite the innovative comparison of the assessment of two opposing renal 
function changes, the focus of these particular analyses were still on the change in renal 
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function on a population level. One possible explanation was put forward by Kataoka, 
suggesting that ‘paradoxical’ improvement of renal function, reflected by a decrease in serum 
creatinine despite worsening heart failure, could be due to inter-individual differences in renal 
function among patients. Moreover, most studies have used merely two time points of 
measurements of serum creatinine to quantify changes in renal function, instead of several 
measurements to form a realistic slope.(5,20,21) Therefore, in this present study we 
thoroughly evaluated each individual renal trajectory and subsequently identified eight 
distinct trajectories of changes of renal function. Of these patterns, a rise in creatinine 
followed by a drop (trajectory ‘Bump’) was most prevalent, whereas an almost absence of 
change in creatinine (trajectory ‘No Change’) was least common. Interestingly, the two most 
opposing trajectories, a sustained increase versus a sustained decrease, had similar baseline 
characteristics. Overall, baseline differences between all trajectories were remarkably small, 
despite the great diversity in the individual changes in renal function patterns. Therefore, it 
might be difficult to establish specific characteristics that identify patients beforehand which 
will experience similar patterns of changes in renal function. 
 
Clinical Outcome and patterns of change in renal function 
In general, WRF in acute HF has been associated with worse clinical outcome, as it is 
independently associated with significantly increased mortality and rehospitalization 
risks.(5,22) However, this does not directly imply that survival improves if treatment causes 
improvement of serum creatinine changes. On the contrary, it has been shown that also 
improved renal function (IRF) as shown by a decrease in serum creatinine is associated with a 
significant, independent, increased risk of mortality, and WRF in the context of 
hemoconcentration is not associated with worse outcomes.(7,18,23) Furthermore, the 
important role of individual risk factors and biomarkers is emphasized, as they provide more 
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prognostic information than the sum of population risk factors.(24) Therefore, this present 
study investigated the prognostic role of the trajectory of serum creatinine as an individual 
renal marker. Overall, our study found that differences in all-cause mortality were small, even 
when adjusted for baseline eGFR. The individual renal pattern that is considered as ‘true’ 
WRF, a continuous increase in creatinine (‘Sustained Increased’), had unexpectedly similar 
outcomes when compared to the opposing trajectory, a constant decrease in creatinine 
(‘Sustained Decrease’), or so called IRF. We were also unable to find other statistically 
significant differences in clinical outcome for any of the trajectories, for all cause mortality 
and the secondary outcomes. Although small differences were observed in crude event rates, 
it is questionable whether this translates into clinically relevant changes. Overall, we found no 
significant evidence for an increased or decreased risk with one particular trajectory.  
 
Possible explanations and clinical implications 
There are several possible explanations for the present findings. One first explanation could 
be the impact of changes in treatment strategies, which were either based on (changes in) 
renal function or actually caused the changes in renal function. Cardiologists routinely assess 
changes in renal function during treatment of acute heart failure, and probably act upon these 
changes in response to therapy. Our findings are therefore a reflection of the general course of 
creatinine, together with the effect of (changes in) decongestive strategies. In this way, 
perhaps, by adjusting therapies, physicians may have overcome some of the excess in risk that 
has been associated with WRF in acute heart failure. Secondly, it is known that heart failure 
patients frequently experience deterioration in renal function prior to hospital admission, as 
well as post-hospital recurrence of renal dysfunction.(18,25) This means that the observed 
inhospital changes in creatinine may only be a reflection of a small part of the entire 
timeframe in which serum creatinine may change. Furthermore, renal function changes should 
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always be evaluated together with the clinical course of the patient.(22)  However, diuretic 
response(26), serving as a surrogate for the clinical course, was not particularly different 
among trajectories, and did not impact the association between trajectories and clinical 
outcome. 
 
Strengths and limitations 
The novelty of this present study is the use of individual patient data to define patterns and 
trajectories of renal function. Individual patient data most accurately reflect real clinical 
practice. Nevertheless, this is a post-hoc analysis and our findings should therefore be 
considered hypothesis generating only. Our study was conducted in a cohort of a randomized 
controlled trial, where treating physicians were unblinded to serum creatinine values, and 
could have consequently altered their treatment regime, resulting in altered risks between 
patients. The in and exclusion criteria of this randomized controlled trial may have resulted in 
selection bias, possibly inducing type I error. Furthermore, our results are limited by the data 
available, as our analysis only includes the first seven days of inhospital events, and therefore 
excludes events prior to hospitalization or post-discharge. For example, a heart failure patient 
who experiences a continuous decrease in creatinine during the first seven days after 
admission might experience a change in renal function after discharge, unknowingly altering 
the individual risk of mortality. It is still difficult to accurately characterize renal function in 
acute heart failure, which could mean that serum creatinine changes in the acute phase do not 
reflect changes in renal function. Furthermore, trajectory assessment was performed by visual 
inspection and might result in a different distribution in the trajectory groups when 
reproduced by different investigators. Additionally, we did not include the magnitude of 
change in creatinine in our analysis, as we focused on the relative change (visual trajectories). 
The trajectory ‘Various Changes’ probably represents a mixed bag of different changes in 
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serum creatinine since the overall change in creatinine in sensitivity analysis was limited. 
Given the large number of defined trajectories, and the known random variation due to the 
creatinine assay or random sampling variation, the true changes in creatinine in each patient could 
have been over and underestimated. Finally, to establish more than one fluctuation in 
creatinine, more than 4 serum creatinine values should be available, therefore, the prevalence 
of the trajectories ’Various Changes’, ‘Bump followed by Dip’ and ‘Dip followed by Bump’ 
may have been underestimated.  
 
Conclusions 
Although there are major differences in patterns of changes in renal function during an acute 
heart failure hospital admission, clinical characteristics and clinical outcome were similar 
between the trajectories. Our results therefore question the prognostic importance of patterns 
of changes in renal function in acute heart failure. 
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Figure Legends 
 
Figure 1. Prevalence and Visual representation of different trajectories of changes in 
renal function 
Dip: a drop followed by a rise, Bump: a rise followed by a drop, Dip followed by Bump: a 
drop followed by a rise and subsequent drop, Bump followed by Dip: a rise followed by a 
drop and a subsequent rise, Sustained Decrease: a continuous decrease, Sustained Increase: a 
continuous increase, No Change: an (almost) absence of change, Various Changes: multiple 
significant fluctuations (not fitting other trajectory) 
 
Figure 2. Different Trajectories and Kaplan Meier of All-cause Mortality at 180 days 
 
Figure 3. Different Trajectories and Kaplan Meier of Death or Cardiovascular or Renal 
rehospitalization at 60 days 
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Table 1. Baseline Characteristics 
Trajectory Bump Sustained 
Increase 
Dip Sustained 
Decrease 
Various 
Changes 
Dip 
followed by 
Bump 
Bump 
followed by 
Dip 
No change P-
value 
N=1897 N=360 N=333 N=275 N=264 N=245 N=208 N=162 N=50  
Demographics          
Sex (% Male) 242 (67) 217 (65) 176 (64) 182 (69) 167 (68) 138 (66) 106 (65) 42 (84) 0.254 
Age (Years) 70 ± 12 72 ± 11 70 ± 12 70 ± 11 69 ± 12 68 ± 12 70 ± 11 68 ± 13 0.064 
Race (% White) 337 (94) 310 (94) 266 (97) 247 (94) 238 (98) 200 (97) 154 (96) 47 (94) 0.150 
Weight (Kg) 80 ± 18 83 ± 19 82 ± 20 82 ± 20 83 ± 20 83 ± 18 78 ± 17 91 ± 23 0.002 
Height (cm) 168 ± 9 169 ± 9 169 ± 9 169 ± 10 169 ± 9 169 ± 9 167 ± 10 170 ± 8 0.253 
Body Mass Index  29 ± 6 29 ± 6 29 ± 7 29 ± 6 29 ± 6 29 ± 6 28 ± 5 31 ± 7 0.026 
LVEF (%) 32 ± 13 33 ± 13 32 ± 12 31 ± 13 32 ± 14 33 ± 13 33 ± 13 31 ± 14 0.638 
SBP (mmHg) 125 ± 17 127 ± 19 124 ± 17 121± 17 124 ± 18 124 ± 17 126 ± 19 124 ± 16 0.020 
DBP (mmHg) 75 ± 11 73 ± 13 74 ± 11 73± 12 75 ± 12 75 ± 11 73 ± 12 72 ± 11 0.050 
Heart Rate 
(beats/min) 
80 ± 15 79 ± 15 80 ± 16 81± 17 81 ± 16 82 ± 15 79 ± 16 80 ± 13 0.130 
Medication          
ACE inhibitor 234 (65) 181 (54) 165 (60) 174 (66) 158 (65) 139 (67) 103 (64) 27 (54) 0.025 
ARB 52 (14) 82 (25) 45 (16) 32 (12) 28 (11) 25 (12) 24 (15) 9 (18) <0.001 
Beta blocker 273 (76) 254 (76) 219 (80) 199 (75) 184 (75) 165 (79) 121 (75) 43 (86) 0.574 
Nitrates 84 (23) 91 (27) 58 (21) 79 (30) 69 (28) 59 (28) 36 (22) 12 (24) 0.199 
Ca channel 
blocker 
53 (15) 60 (18) 33 (12) 27 (10) 23 (9) 26 (13) 25 (15) 10 (20) 0.033 
MRA 159 (44) 148 (44) 111 (40) 115 (44) 107 (44) 105 (51) 74 (46) 24 (48) 0.607 
Medical History          
Angina (N(%)) 79 (22) 67 (20) 57 (21) 65 (25) 65 (27) 45 (22) 33 (21) 9 (18) 0.572 
AF 185 (51) 166 (50) 160 (59) 160 (61) 131 (54) 107 (52) 87 (55) 28 (60) 0.126 
Smoking 71 (20) 81 (24) 53 (19) 52 (20) 54 (22) 37 (18) 32 (20) 14 (28) 0.500 
NYHA         <0.001 
I/II 64 (19) 81 (26) 46 (18) 26 (10) 42 (18) 30 (15) 25 (16) 6 (12)  
III 174 (51) 169 (54) 139 (54) 116 (46) 120 (52) 94 (47) 79 (51) 28 (56)  
IV 103 (30) 65 (21) 75 (29) 111 (44) 69 (30) 75 (38) 50 (33) 16 (32)  
Diabetes Mellitus 153 (43) 157 (47) 138 (50) 115 (44) 115 (47) 92 (44) 68 (42) 25 (50) 0.540 
Hypertension 277 (77) 281 (84) 213 (78) 214 (81) 192 (78) 173 (83) 123 (76) 36 (72) 0.090 
Ischemic HD 249 (69) 247 (74) 194 (71) 181 (69) 154 (63) 144 (69) 110 (68) 41 (82) 0.092 
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MI 174 (48) 180 (54) 139 (51) 130 (49) 107 (44) 105 (51) 77 (48) 32 (64) 0.157 
PCI 92 (26) 112 (34) 74 (27) 59 (23) 54 (22) 42 (20) 35 (22) 23 (47) <0.001 
Stroke (bey. 2yr) 26 (7) 33 (10) 23 (8) 27 (10) 17 (7) 22 (11) 17 (11) 7 (14) 0.521 
 
Biomarkers          
Albumin (g/dL) 
 
3.9 (3.7-4.2) 3.9 (3.6-4.1) 3.9 (3.7-4.1) 3.8 (3.6-4.1) 3.9 (3.6-4.2) 3.8 (3.6-4.15) 3.9 (3.6-4.2) 3.8 (3.6-4.15) 0.005 
Chloride (mEq/L) 
 
101 (98-105) 102 (99-105) 101 (99-104) 101 (97-105) 102 (99-104) 102 (99-104) 102 (97-104) 102 (100-106) 0.035 
Cholesterol, Total 
(mg/dL) 
148 (123-180) 146 (115-176) 141 (117-163) 132 (107-164) 158 (127-188) 147 (122-168) 152 (125-185) 146 (124-171) 0.001 
Glucose, random, 
Serum (mg/dL) 
127 (97-164) 123 (103-154) 146 (117-207) 124 (102-167) 133 (106-175) 133 (108-181) 117 (92-138) 133 (121-191) 0.004 
Potassium 
(mEq/L) 
4.2 (3.9-4.6) 4.2 (3.8-4.6) 4.3 (3.9-4.7) 4.4 (3.9-4.9) 4.2 (3.9-4.7) 4.2 (3.9-4.7) 4.25 (3.9-4.6) 4.5 (3.95-4.85) 0.097 
Sodium (mEq/L) 
 
140 (138-142) 140 (138-143) 140 (137-143) 139 (137-142) 141 (138-143) 140 (138-142) 139 (137-142) 140 (139-143) 0.012 
Uric Acid (mg/dL) 
 
8.4 (6.8-10.4) 8.8 (7.2-10.3) 8.8 (7.4-10.5) 9.4 (7.6-11.3) 7.9 (6.4-10.1) 8.8 (7.1-10.1) 8.5 (7.2-10.1) 9.1 (6.8-10.3) <0.001 
eGFR 
(mL/min/1.73m
2
) 
50.66 ± 20.75 49.14 ± 20.26 50.22 ± 19.59 43.63 ± 16.27 56.47 ± 21.92 51.12 ± 18.57 55.59 ± 20.50 54.06 ± 22.26 <0.001 
Creatinine 
(mg/dL) 
 
1.40 
(1.10-150) 
1.40 
(1.10-1.80) 
1.40 
(1.10-1.70) 
1.60 
(1.30-2.10) 
1.20 
(1.10-1.50) 
1.40 
(1.10-1.80) 
106 
(1.00-1.50) 
1.50 
(1.20-2.00) 
<0.001 
Hct (%) 
 
40.2 ± 6.2 38.7 ± 5.6 40.5 ± 6.3 40.5 ± 6.2 41.6 ± 6.2 40.9 ± 6.4 40.3 ± 6.2 40.2 ± 5.5 <0.001 
Hgb (g/dL) 
 
12.7 ± 1.9 12.2 ± 1.8 12.7 ± 2.0 12.7 ± 2.0 13.2 ± 2.0 12.8 ± 2.0 12.9 ± 2.1 12.6 ± 1.9 <0.001 
BUN (mg/dL) 28 (22-39) 31 (22-38) 30 (22-42) 37 (26-50) 27 (21-35) 29 (21-40) 25 (20-35) 29 (22-38) <0.001 
BNP (pg/mL) 406 (248-735) 408 (247-694) 440 (267-860) 612 (296-
1007) 
432 (253-745) 484 (257-797) 415 (266-780) 443 (219-654) 0.002 
 
Clinical 
symptoms 
         
Dyspnea on 
Exertion 
353 (99.7) 321 (100.0) 275 (99.6) 262 (100.0) 234 (100.0) 203 (100.0) 158 (100.0) 48 (100.0) 0.781 
Severe Dyspnea  199 (56.2) 161 (50.2) 154 (88.8) 159 (60.7) 149 (63.7) 126 (62.1) 94 (59.5) 25 (52.1) 0.037 
JVP (>10 cm) 123 (37.4) 131 (42.5) 122 (47.7) 99 (41.4) 88 (40.2) 82 (43.4) 41 (27.9) 22 (44.9) 0.012 
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Orthopnea (>3 pil) 148 (41.3) 139 (41.9) 129 (46.7) 125 (46.8) 105 (43.4) 88 (43.1) 73 (45.1) 22 (44.0) 0.836 
Edema >3+ 90 (24.9) 77 (22.6) 78 (28.1) 89 (33.2) 78 (31.8) 61 (29.3) 37 (22.7) 15 (29.4) 0.045 
Rales >2/3 34 (9.4) 30 (8.8) 25 (9.0) 27 (10.1) 36 (14.8) 21 (10.1) 11 (6.7) 2 (3.9) 0.129 
Diuretic response 
(kg/40 mg 
Furosemide) 
-0.33 (-0.70 - 
-0.11) 
-0.33 (-0.78 - 
-0.10) 
-0.44 (-0.83 - 
-0.22) 
-0.41 (-0.78 - 
-0.14) 
-0.46 (-0.97 - 
-0.16) 
-0.44 (-0.91 - 
-0.18) 
-0.36 (-0.71 - 
-0.14) 
-0.26 (-0.47 - 
-0.14) 
0.001 
Outcome          
Death day 180 59 (16.3) 68 (20.0) 43 (15.5) 51 (19.0) 41 (16.7) 25 (12.0) 24 (14.7) 7 (13.7) 0.321 
Death or HF 
rehospitalization 
day 60 
83 (22.9) 82 (24.1) 55 (19.8) 59 (22.0) 36 (14.7) 40 (19.2) 33 (20.2) 15 (29.4) 0.111 
Cardiovascular 
or renal 
rehospitalization 
97 (26.8) 89 (26.2) 61 (21.9) 58 (21.6) 49 (20.0) 45 (21.6) 33 (20.2) 17 (33.3) 0.176 
Values are given as means ± standard deviation, median (interquartile range) or percentage and frequency 
ACE=angiotensin converting enzyme, AF=atrium fibrillation, ARB=angiotensin receptor blocker, BNP=Brain natriuretic peptide, 
DBP=Diastolic blood pressure, Hct=Hematocrit, HD=Heart disease, Hgb=Hemoglobin, HR=Heart rate, JVP=Jugular venous pressure, 
MI=Myocardial infarction, MRA: Mineralocorticoid Receptor Antagonist, PCI=percutaneous coronary intervention, SBP=Systolic blood 
pressure 
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Table 2. Cox survival analysis for predicting 180-day mortality 
Trajectory  Number 
of 
patients 
(N (%)) 
HR (95% CI)
 
P-value HR (95% CI)
* 
P-value HR (95% CI)
** 
P-
value 
No Change 50 Ref. 0.52 Ref. 0.57 Ref. 0.46 
Bump 360 1.35 (0.58-3.13) 0.48 1.40 (0.60-3.24) 0.43 1.53 (0.66-3.57) 0.32 
Sustained Increase 333 1.59 (0.69-3.68) 0.28 1.57 (0.68-3.63) 0.29 1.59 (0.68-3.69) 0.28 
Dip 275 1.24 (0.53-2.93) 0.62 1.24 (0.52-2.92) 0.63 1.27 (0.54-3.02) 0.58 
Sustained Decrease 264 1.58 (0.68-3.70) 0.29 1.41 (0.60-3.30) 0.43 1.19 (0.51-2.79) 0.69 
Various Changes 245 1.43 (0.61-3.36) 0.42 1.67 (0.71-3.93) 0.24 1.74 (0.73-4.13) 0.21 
Dip followed by Bump 208 1.00 (0.41-2.44) 1.00 1.02 (0.42-2.49) 0.96 1.11 (0.45-2.73) 0.82 
Bump followed by Dip 162 1.22 (0.50-2.99) 0.68 1.38 (0.56-3.40) 0.49 1.45 (0.59-3.59) 0.42 
*. Model 2. Renal trajectories adjusted for estimated GFR. 
**. Model 3. Renal trajectories adjusted for age of subject, systolic blood pressure, HF hospitalization in past year, severity of edema, baseline 
albumin (g/dL), sodium (mEq/L), blood urea nitrogen (BUN) (mg/dL), and creatinine (mg/dL). 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
24 
 
Figure 1. Prevalence and Visual representation of different trajectories of changes in 
renal function 
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Figure 2. Different Trajectories and Kaplan Meier of all-cause mortality at 180 days 
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Figure 3. Different Trajectories and Kaplan Meier of Death or cardiovascular or renal 
rehospitalization at 60 days 
 
 
